Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103


Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens.

Villa CH, Dao T, Ahearn I, Fehrenbacher N, Casey E, Rey DA, Korontsvit T, Zakhaleva V, Batt CA, Philips MR, Scheinberg DA.

ACS Nano. 2011 Jul 26;5(7):5300-11. doi: 10.1021/nn200182x. Epub 2011 Jun 23.


Defining MHC class II T helper epitopes for WT1 tumor antigen.

Kobayashi H, Nagato T, Aoki N, Sato K, Kimura S, Tateno M, Celis E.

Cancer Immunol Immunother. 2006 Jul;55(7):850-60. Epub 2005 Oct 12.


One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.

Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM.

J Immunol. 2005 Feb 1;174(3):1751-9.


A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes.

Rajnavölgyi E, Nagy N, Thuresson B, Dosztányi Z, Simon A, Simon I, Karr RW, Ernberg I, Klein E, Falk KI.

Int Immunol. 2000 Mar;12(3):281-93.


Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.

Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, van der Bruggen P, Schuler G.

J Immunol. 2004 Jan 15;172(2):1304-10.


Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.

May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4547-55. Erratum in: Clin Cancer Res. 2007 Sep 1;13(17):5226.


Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy.

Ikuta Y, Katayama N, Wang L, Okugawa T, Takahashi Y, Schmitt M, Gu X, Watanabe M, Akiyoshi K, Nakamura H, Kuribayashi K, Sunamoto J, Shiku H.

Blood. 2002 May 15;99(10):3717-24.


A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.

Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D.

Eur J Immunol. 2005 Apr;35(4):1066-75.


Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.

Karbach J, Pauligk C, Bender A, Gnjatic S, Franzmann K, Wahle C, Jäger D, Knuth A, Old LJ, Jäger E.

Int J Cancer. 2006 Feb 1;118(3):668-74. Erratum in: Int J Cancer. 2006 Oct 1;119(7):1753.


Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.

Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ.

Clin Cancer Res. 2005 May 1;11(9):3446-54.


Carbon nanotubes' surface chemistry determines their potency as vaccine nanocarriers in vitro and in vivo.

Hassan HA, Smyth L, Rubio N, Ratnasothy K, Wang JT, Bansal SS, Summers HD, Diebold SS, Lombardi G, Al-Jamal KT.

J Control Release. 2016 Mar 10;225:205-16. doi: 10.1016/j.jconrel.2016.01.030. Epub 2016 Jan 21.


A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules.

Sexton A, Whitney PG, Chong SF, Zelikin AN, Johnston AP, De Rose R, Brooks AG, Caruso F, Kent SJ.

ACS Nano. 2009 Nov 24;3(11):3391-400. doi: 10.1021/nn900715g.


IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.

Bianchi R, Grohmann U, Belladonna ML, Silla S, Fallarino F, Ayroldi E, Fioretti MC, Puccetti P.

J Immunol. 1996 Aug 15;157(4):1589-97.


Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain.

Voutsas IF, Gritzapis AD, Mahaira LG, Salagianni M, von Hofe E, Kallinteris NL, Baxevanis CN.

Int J Cancer. 2007 Nov 1;121(9):2031-41.


Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.

Kobayashi H, Wood M, Song Y, Appella E, Celis E.

Cancer Res. 2000 Sep 15;60(18):5228-36.

Supplemental Content

Support Center